Enfortumab vedotin-ejfv

Enfortumab vedotin-ejfv is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3) conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine-citrulline (vc) linker (SGD-1006). Conjugation takes place on cysteine residues that comprise the interchain disulfide bonds of the antibody to yield a product with a drug-to-antibody ratio (DAR) of approximately n = 3.6. The molecular weight is approximately 152 kDa. This product is for research use only.

Product Details
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Enfortumab (AGS-22C3)
ADC cytotoxin (drug)	MMAE
Immunogen	Nectin-4
DAR (Drug to Antibody Ratio)	~3.6
Purity	99%
Molecular Weight	152kDa
Protein Concentration	10mg/ml
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	100 mM Pro-Ac, 20 mM Arg, pH 5.0